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Abstract Infection of cell cultures with cell-free virus
isolated from HIV-infected patients is notoriously difﬁcult
and results in a loss of viral variation. Here, we describe
viral sequences from PBMC, U87.CD4.CCR5 and
U87.CD4.CXCR4 cell cultures and compare them to those
from blood plasma from 12 patients from whom virus
particles were isolated using CD44 MicroBeads. In both
PBMC and U87.CD4.CCR5 cultures, 66% of the plasma
viral strains were retrieved after culturing. In addition, co-
receptor use was predicted based on the env-V3 sequence
and tested in U87.CD4 cells expressing either CCR5 or
CXCR4. Recovery was lower for the CXCR4-using viruses.
Only 50% of the virus clusters predicted to use CXCR4
could be retrieved from cell cultures, while 71% of CCR5-
using strains were found in U87.CCR5 cultures. Therefore,
isolation of primary viruses with CD44 MicroBeads results
in a good representation in cell culture of the in vivo
divergence.
Introduction
For a virus that has established a worldwide epidemic,
human immunodeﬁciency virus type 1 (HIV-1) virus
particles have a surprisingly low infectivity in vitro. These
low infectivity-to-particles ratios, ranging from 10
-4 to
10
-7 [1], are multifactorial. Factors include the time of
absorption, the concentration of the virus, the target cell
type and concentration, the diffusion coefﬁcient and the
half-life of the virus [2, 3]. For the target cells used in the
assays, both the radius and number of receptors available
are factors of importance in retroviral infection. In addi-
tion, retrovirus preparations contain defective particles,
although probably not as many as previously suggested [4].
Also, virus particles from patient samples can be bound by
host proteins, e.g. complement factors, immunoglobulins or
soluble CD4 (sCD4), which can inﬂuence infectiousness.
Many of these aspects inﬂuencing infectivity are either
inherent to the virus and cannot be changed or are at least
difﬁcult to manipulate. Because of the limitations of par-
ticle infectivity, isolation of replication-competent virus
from HIV-infected patients is mainly done by coculture of
patient PBMCs with donor cells [5, 6]. This technique has
the disadvantage that it can reactivate latent, archival
strains that do not reﬂect the current replicating virus pool
[7, 8], and it can severely reduce viral variation [9, 18].
Therefore, optimization of virus particle infectiousness has
beenthetargetofmanystudiessincethediscoveryofHIV,as
there is a growing need to obtain primary isolates for neu-
tralization assays, vaccine studies, determination of tropism,
anddrugtesting.Varyingthetargetcellorvirusconcentration
has some effect on the infectivity of HIV-1 [1, 2], but more
important enhancements have been achieved by increasing
particle absorption to target cells through the addition of
polybrene [7], by spinoculation [10], by Magnetofection [4],
or with the help of CD44 MicroBeads [11]. These methods
also work with serum or plasma virus from HIV-1-infected
patients if viral copy numbers are adequate (generally
[100,000 copies vRNA/ml).
An issue in HIV infections is the type of coreceptor
molecule bound by the viral envelope proteins of the par-
ticle to enter cells. In most cases, this is either one of the
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common coreceptor molecule, used by almost all primary
HIV-1 strains. CXCR4 use, on the other hand, is an ability
that arises later in infection and is associated with disease
progression. Infecting U87.CD4 cells, a glioblastoma cell
line engineered to express both the HIV CD4 receptor and
an HIV coreceptor molecule, is the current method of
choice when analysing HIV tropism. It is not known how
much virus variation is regained when infecting U87.CD4
cells with primary isolates. Therefore, we have analysed
the percentage recovery of the actual replicating virus
population when using CD44 MicroBeads to isolate plasma
virus and PBMCs or U87.CD4 cells expressing either
CCR5 or CXCR4 to culture the primary strains of different
HIV-1 subtypes. Virus particles were isolated from blood
plasma of 12 HIV-1-infected patients. Viral clusters found
in blood plasma, as determined by sequencing and phylo-
genetic analysis, were compared with the clusters found
subsequently in the cell cultures so that the loss of variation
experienced after in vitro infection could be estimated. In
addition, coreceptor use of the different clusters was pre-
dicted genotypically and compared with the U87.CD4 cell
culture outcome to determine if certain coreceptor-using
virus variants were selectively lost.
Materials and methods
Patient characteristics
Twelve HIV-1-infected patients seen at the Academic
Medical Centre (AMC) of the University of Amsterdam
(Amsterdam, The Netherlands) were selected for this study
based on their plasma viral load and HIV-1 subtype. Patient
characteristics are summarized in Table 1. Blood plasma
HIV-1 RNA levels were measured with the VERSANT
HIV-1 RNA 3.0 assay (bDNA) (Bayer Diagnostics Divi-
sion, Tarrytown, NY, USA). Plasma viral load ranged from
31,092 to 2,119,621 copies/ml. HIV-1 subtypes included
were subtype A (49), subtype B (39), subtype D (19),
CRF01_AE (19), CRF02_AG (29) and CRF06_cpx (19).
The current study showed that the patient infected with
a subtype D strain, as indicated by direct sequence analy-
sis of the pol gene in a genotyping assay, was actually
infected with two HIV-1 strains: a subtype D and a subtype
C strain.
Virus isolation
Blood plasma virus was isolated from 450 ll of plasma
with the lMACS
TM VitalVirus HIV Isolation Kit (Miltenyi
Biotec B.V., Benelux) according to the manufacturer’s
instructions. Isolated virus was eluted in 200 ll.
Cell culture
U87.CD4 glioblastoma cells expressing either CCR5 or
CXCR4 were used to determine coreceptor tropism of the
blood plasma viruses isolated with the help of CD44
MicroBeads from 12 HIV-1 infected patients [12]. As a
control, CD8? T-cell-depleted interleukin-2 (Proleukin,
Chiron, Emeryville, CA.) and phytohemagglutinin (bio-
TRADINGBenelux,Mijdrecht,TheNetherlands)-stimulated
PBMC pooled from at least three uninfected donors were
infected with the plasma virus isolates. CD8? Tc e l ld e p l e -
tionwasdoneafter2 daysusingaDynabeadsM-450CD8kit
(Invitrogen Corporation, Carlsbad, CA). PBMCs were cul-
tured in RPMI 1640 medium (Invitrogen Corporation,
Carlsbad, CA.) supplemented with 10% heat-inactivated
foetal calf serum (FCS). U87 cells were cultured in DMEM
(Invitrogen Corporation, Carlsbad, CA.), also supplemented
with 10% heat-inactivated FCS. For the U87 cells, 2.5 9 10
5
cells were used per infection with 50 ll isolated virus, while
for the PBMCs, 2 9 10
5 cells were used per infection with
100 ll of isolated virus. On days 2, 6, 9 and 14, culture
supernatant was analysed with an in-house gag-p24 antigen
capture enzyme-linked immunosorbent assay (ELISA) to
monitor virus production. In addition, syncytia were scored
using a microscope. Positive controls were infections of
U87.CCR5orU87.CXCR4cellswiththeHIV-1CCR5-using
strains JR-FL (detection limit in U87.CCR5 cells: 10,000
copies vRNA), SF162 (detection limit in U87.CCR5 cells:
1,000 copies vRNA) and the CXCR4-using strain Lai
(detection limit in U87.CXCR4 cells: 300 copies vRNA).
PCR ampliﬁcation and sequence analysis
RNA was isolated from plasma samples and from cell cul-
tures by a method using silica and guanidium thiocyanate
Table 1 Patient and blood plasma virus characteristics
Patient
no. ($/#)
Subtype (based
on the env gene)
pVL copies/ml CD4? T cell count
(910
6 cells/ml)
P99-01 # CRF02_AG 180,000 \50
P03-01 # CRF01_AE 160,000 10
P04-01 # A 1,300,000 140
P07-01 # CRF06_cpx 434,536 \40
P07-02 $ A1 2,119,621 220
P07-03 # A 242,573 90
P07-04 $ CRF02_AG 212,595 70
P07-05 $ B 31,092 240
P07-06 $ A 605,399 120
P09-01 # B 138,205 670 (PHI
a)
P09-02 # B 527,746 300
P09-03 $ C ? D 456,089 20
a Primary HIV infection
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123[13]. A fragment of the HIV-1 env gene encompassing the
V3 and V4 regions (nt 6950-7509 of the HXB2 reference
sequence, GenBank Acc. No. K03455) was reverse tran-
scribed, ampliﬁed, cloned using a TOPO TA Cloning Kit
(Invitrogen, Carlsbad, CA.), and sequenced using a BigDye
Terminator Cycle Sequencing Kit (Applied Biosystems,
FosterCity,CA.)asdescribed[14].Electrophoresisanddata
collection were performed on an ABI PRISM 3100 Genetic
Analyser(alsofromAppliedBiosystems).Atleast15clones
were analysed for each sample.
Phylogenetic analysis and tropism prediction
The number of HIV-1 env sequence clusters present in
each plasma sample was determined by phylogenetic
analysis with the MEGA4 software package distributed
by Sudhir Kumar, Arizona State University, Tempe
(http://www.megasoftware.net). Distances were estimated
by the Tamura-Nei method [15], using the gamma model to
correct for multiple hits and to account for excess transi-
tions, unequal nucleotide frequencies, and variation of the
substitution rate among different sites. The shape param-
eter alpha, which describes the variation across sites by a
gamma distribution, was set at 0.38 [16]. Phylogenetic
trees were generated by the neighbour-joining method and
bootstrap resampling with 1,000 replicates. The coreceptor
use of a representative sequence of each cluster was
predicted using both the 11/25 rule and the Geno2pheno
coreceptor option available at http://coreceptor.bioinf.mpi-
inf.mpg.de/index.php.
Results
U87.CD4 cell culture results
Virus was isolated with the aid of CD44 MicroBeads from
12 plasma samples with viral loads ranging from 31,092 to
2,119,621 copies/ml and harbouring different subtypes of
HIV-1 group M (Table 1). One hundred microliter of virus
was used to infect 2 9 10
5 PBMCs as a positive control,
and 50 ll was used to infect either U87.CD4.CCR5 or
U87.CD4.CXCR4 cells. Eleven out of twelve PBMC cul-
tures became p24-antigen positive; one isolate did not grow
in PBMC (Table 1). This isolate also did not grow in
U87.CD4 cells, probably due to its low concentration
(±30,000 copies/ml). Ten out of twelve virus isolates
replicated in U87.CD4.CCR5 cells (Table 1), while three
U87.CD4.CXCR4 cultures were productively infected, as
monitored both by p24 antigen production and syncytium
formation. The virus isolates successfully growing in
U87.CD4.CXCR4 cultures also scored positive in the
accompanying U87.CD4.CCR5 culture, suggesting that the
patients from whom they originated harboured both CCR5-
and CXCR4-using viruses, either as monotropic lineages or
as dual-tropic viruses.
HIV-1 variation and coreceptor use
Viral lineages present in the patient’s blood plasma were
identiﬁed by phylogenetic analysis of env clones. The HIV-1
subtype was determined using the same env fragment,
and this conﬁrmed the original subtype classiﬁcation based
on the pol gene. For each cluster of sequences, coreceptor
use was predicted in silico with both the geno2pheno
[coreceptor] algorithm and the 11/25 rule, which is based
upon the presence of charged amino acids at positions 11
and 25 of the env-V3 loop (Table 2). To identify viral
Table 2 Geno/phenotype of plasma-derived HIV-1 isolated with
CD44 beads
Patient
no.
Env cluster
no. (plasma)
Geno2pheno
prediction
11/25
rule
PBMC
growth
U87.R5 and/
or U87.X4
P99-01 1 R5 R5 ? R5
2R 5 R 5 - R5
P03-01 1 X4 R5 ? R5
2X 4 X 4 - X4
P04-01 1 X4 X4 ? X4
2R 5 R 5 ? R5
3X 4 X 4 ? R5, X4
P07-01 1 R5 R5 - R5
2R 5 R 5 - R5
P07-02 1 R5 X4 - –
2R 5 R 5 ? R5
3R 5 R 5 ? R5
4R 5 R 5 ? –
5R 5 R 5 ? R5
P07-03 1 R5 R5 - R5
2R 5 R 5 - –
3R 5 R 5 ? R5
P07-04 1 X4 X4 ? –
2X 4 X 4 ? –
3R 5 R 5 - R5
P07-05 ND ND ND - –
P07-06 1 R5 R5 - –
2R 5 R 5 ? –
P09-01 1 R5 R5 ? R5
P09-02 1 R5 R5 ? –
2R 5 R 5 ? –
3R 5 R 5 ? R5
P09-03 1 X4 X4 ? X4
2X 4 X 4 - –
3R 5 R 5 ? R5
ND Not determined
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123strains capable of infecting speciﬁc cell cultures, viral
RNA from each culture was also reverse-transcribed,
PCR ampliﬁed, sequenced and analysed. Viral diversity
in patients ranged from a virtually homogeneous popu-
lation in a patient with an acute HIV infection (patient
P09-01) to 5 separate virus clusters in a patient in the
chronic phase of infection (patient P07-02) (Table 2).
Most samples contained 2–3 distinct HIV-1 sequence
clusters (Fig. 1). Genotypic prediction was usually in
line with phenotypic outcome (Table 2). In four patients
(P03-01, P04-01, P07-04, and P09-03), CXCR4 use was
predicted for some clusters. For three of these patients,
representative env-V3 sequences are shown in Fig. 2.I n
patient P03-01, one of the clusters predicted to use
CXCR4 by the Geno2pheno algorithm but CCR5 by the
11/25 rule was actually only found in the CCR5 culture.
The other cluster, also predicted to use CXCR4, was
indeed found in the U87.CXCR4 culture. In patient
P04-01, one of the clusters predicted to be able to use
CXCR4 was in fact a dual-tropic strain that was also
found in the U87.CCR5 culture. For patient P07-04,
CXCR4 use was predicted for two HIV-1 sequence
clusters present in plasma, but repeated experiments did
not show any growth in U87.CXCR4 cultures. However,
infection of MT-2 cells, a cell line that only supports
CXCR4-using HIV strains, produced gag-p24 after
infection with virus isolated from patient P07-04 and
formed syncytia, both of which are indicative of virus
production [17]. This suggests that the MT-2 cell line is
more sensitive to infection with CXCR4-using HIV than
U87.CXCR4 cells are. Alternatively, the CXCR4 vari-
ants found in this patient could have further requirements
for infection that go beyond coreceptor expression.
Surprisingly, viruses isolated from patient P07-06 grew
in PBMCs but not in U87.CD4 cell culture, suggesting a
very low infectivity despite a plasma viral load (pVL) of
[600,000 copies/ml.
Overall, 71% of virus clusters predicted to use CCR5
as a coreceptor were indeed retrieved from U87.CCR5
cultures, but for CXCR4-using viruses, recovery was only
around 50%. This suggests that U87.CXCR4 cells are less
sensitive to HIV infection or that CXCR4-using variants
are minor variants in blood, resulting in a lower viral
load, making them less efﬁcient in in vitro infection.
Also, some viruses could have been derived from early
switchers that do not yet have the optimal ability to use
CXCR4.
In patient P09-03, an unexpected dual infection with
HIV-1 subtypes C and D was found, in which both sub-
types were present in almost equal amounts in the plasma
sample. Initial genotyping based upon a direct sequence
from the pol gene suggested that this patient was infected
with only a subtype D virus. Culturing of the plasma virus
showed that subtype C was solely present in the U87.CCR5
cells, while subtype D sequences were exclusively found in
the U87.CXCR4 cells. Both subtypes were found in the
PBMC culture.
Besides the subtype D virus, CXCR4-using viruses in
this study were a subtype A virus and the recombinant
strain CRF01_AE. CRF02_AG variants from patient
P07-04 were predicted to use CXCR4 but were not found
in culture. All patients harbouring CXCR4-using viruses
had CD4? T cell counts\150 cells/ll.
0.02
P03-01
Cluster 1
Cluster 2
100
100
100
0.01
P04-01
Cluster 2
Cluster 1
Cluster 3
99
100
0.05
P09-03
Cluster 3
Cluster 2
Cluster 1
Subtype D
Subtype C
Fig. 1 Phylogenetic analysis of HIV env-V3 sequences. Neighbour-
joining trees of blood plasma HIV-1 env-V3 sequences of three
representative patients, P03-01 (CRF01_AE), P04-01 (subtype A),
and P09-03 (subtypes C and D), are shown. Sequence clusters were
identiﬁed using the trees and used for subsequent classiﬁcation of
sequences retrieved from cell cultures. The blood plasma minority
sequence from patient P03-01, represented by a single sequence
(labelled cluster 2), was faithfully retrieved from U87.CXCR4
cultures. The single sequence of patient P09-03, labelled cluster 2,
was not retrieved from any cell culture. Genetic distances are
indicated. Bootstrap values C90 are shown
2020 M. Cornelissen et al.
123Discussion
We demonstrate here that isolation of virus particles from
blood plasma utilizing CD44 MicroBeads is an improved
method for generating primary isolates from patients [11].
Standard techniques for isolation of HIV-1 from blood
plasma are notoriously difﬁcult and usually result in the
selection of a low number of viral variants. This causes
problems in studies where the aim is to amplify represen-
tative viruses for subsequent phenotypic analysis, such as
in vaccine or antiretroviral drug trials. Additionally, assays
that are quick and relatively easy to perform as well as cost
effective would be a major asset in the ﬁeld. Here, we have
analysed how effective CD44 MicroBeads are for retriev-
ing representative HIV-1 isolates from clinical samples
from HIV-infected patients. Plasma viruses from twelve
patients harbouring various HIV-1 subtypes were iso-
lated and used to infect PBMCs, U87.CD4.CCR5 and
U87.CD4.CXCR4 cells. For nine patient isolates, both
PBMC and U87.CD4 cultures supported viral growth. For
two other patients, not all cultures became infected; the
PBMC culture was negative in the case of patient P07-01,
and the U87.CD4 cultures were negative for p24 antigen in
the case of patient P07-06. The plasma viral load of both
patients was relatively high: [400,000 and [600,000
copies/ml, respectively, but the infectious titre was not
determined. The ratio of infectious to total particles varies
widely among patients, and has been found to be charac-
teristic for a certain patient (or virus) over time [7]. Very
high plasma viral loads with low infectious titres have been
described [7].
Only one out of twelve patient isolates was consistently
negative in all cell cultures. The plasma viral load of this
patient was the lowest of all: approximately 30,000 copies/
ml. This number translates into ±3,500 virus particles in
the PBMC infection and ±1,750 particles each for the
U87.CD4 cell cultures. However, the infectious viral load
of this patient may be much lower. In an earlier study, the
median ratio of infectious to total particles in patients with
a plasma viral load between 10,000 and 100,000 copies/ml
and a measurable infectious titre (79% of patients in this
pVL class) can be calculated to be around 1/4,700 [7]. It is
therefore likely that there are no or very few infectious
particles in the isolates obtained from this patient’s plasma.
Selection and lineage reduction are an important prob-
lem associated with cell culture [9, 18]. A total of 29 dif-
ferent sequence clusters were detected in the plasma of 11
HIV-1-infected patients. Of these clusters, 19 (66%) were
retrieved from PBMC cultures, and another 19 were from
U87.CD4 cell cultures, indicating that approximately 2/3 of
the variation present in plasma is recovered by culturing.
For individual patients, culture outcome varied slightly.
For three patients, an equal number of clusters were
retrieved from both PBMC and U87 cultures. For four
other patients, more clusters were obtained from PBMC
culture than from U87 cultures. For the remaining four
patients, the situation was reversed, with more clusters
being retrieved from U87 cultures than from PBMCs. It is
likely that sequencing more clones will result in the
detection of additional clusters. Only in one patient with
more than one sequence cluster, P04-01, were all plasma
variants detected in the cell cultures. This patient had a
very high pVL of 1,300,000 copies/ml and possessed not
only CCR5- and CXCR4- using variants but also a dual-
tropic strain.
Isolation of HIV particles from blood plasma with the
help of CD44 MicroBeads and subsequent infection of
PBMCs or U87.CD4 cells resulted in an average retrieval
of 50–66% of the virus clusters present in blood. Possibly,
improvement could be achieved by infecting U87 cells
Fig. 2 Env-V3 sequences from patients P03-01, P04-01 and P09-03.
The translated amino acid sequence of a representative env-V3 loop
of the clusters found in plasma samples and subsequent cell cultures is
shown for patients P03-01, P04-01, and P09-03. The number of clones
belonging to the indicated env-V3 cluster recovered from blood
plasma or cell cultures is shown. All three patients harboured
CXCR4-using viruses. Coreceptor predictions by the Geno2pheno
algorithm and the 11/25 rule, which generally agree, are indicated.
*Geno2pheno prediction = X4; 11/25 rule prediction = R5
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123with larger volumes of isolated virus, or by initially iso-
lating virus from larger volumes of plasma. Although
additional optimization is required, infecting U87.CD4
cells expressing either CCR5 or CXCR4 could be a new
and convenient method for determination of tropism, since
no ampliﬁcation or cloning steps are required. However,
plasma viral loads need to be substantial, in excess of
30,000 copies/ml.
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